These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18326967)

  • 1. Beta-blockers in the treatment of hypertension: new data, new directions.
    Weber MA; Bakris GL; Giles TD; Messerli FH
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):234-8. PubMed ID: 18326967
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA; Black HR
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Realities of newer beta-blockers for the management of hypertension.
    Manrique C; Giles TD; Ferdinand KC; Sowers JR
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vasodilating beta blockers as effective antihypertensive agents. Results of a multicenter observational study].
    von Fallois J; Faulhaber HD
    MMW Fortschr Med; 2000 Jun; 142(24):45. PubMed ID: 10895582
    [No Abstract]   [Full Text] [Related]  

  • 8. [Nephroprotective properties of third-generation beta-adrenoblockers].
    Kuz'min OB; Belianin VV; Zhezha VV
    Eksp Klin Farmakol; 2014; 77(3):40-3. PubMed ID: 24800526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aortic elastic properties : effects of carvedilol versus nebivolol.
    Sayin MR; Aydin M; Dogan SM; Karabag T; Cetiner MA; Aktop Z
    Herz; 2013 May; 38(3):299-305. PubMed ID: 23263241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.
    Studinger P; Tabák ÁG; Chen CH; Salvi P; Othmane TE; Torzsa P; Kapocsi J; Fekete BC; Tislér A
    J Clin Hypertens (Greenwich); 2013 Dec; 15(12):910-7. PubMed ID: 24119182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
    Frishman WH; Henderson LS; Lukas MA
    Vasc Health Risk Manag; 2008; 4(6):1387-400. PubMed ID: 19337551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of carvedilol in hypertension: an update.
    Leonetti G; Egan CG
    Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents.
    Coats AJ
    Drugs Aging; 2006; 23(2):93-9. PubMed ID: 16536633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol.
    Giles TD
    Am J Med; 2010 Jul; 123(7 Suppl 1):S16-20. PubMed ID: 20609694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
    Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
    Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol: a review.
    Cockcroft J
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvedilol outclasses the other beta-blockers.
    Cardiovasc J S Afr; 2001; 12(2):120-1. PubMed ID: 11474696
    [No Abstract]   [Full Text] [Related]  

  • 19. [Nebivolol: a beta blocker with vasodilator properties].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(15):631-3. PubMed ID: 10804847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with dual-acting drugs in hypertension.
    Rahn KH
    Clin Investig; 1992; 70 Suppl 1():S39-42. PubMed ID: 1350483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.